Avalo Therapeutics
AVTX
20 hedge funds and large institutions have $84.7M invested in Avalo Therapeutics in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
15% more capital invested
Capital invested by funds: $73.5M → $84.7M (+$11.3M)
11% more funds holding
Funds holding: 18 → 20 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.86% less ownership
Funds ownership: 53.89% → 52.03% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.95M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$315K |
| 3 |
Millennium Management
New York
|
+$288K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$170K |
| 5 |
Goldman Sachs
New York
|
+$78.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$114K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$64K |
| 3 |
Barclays
London,
United Kingdom
|
-$42K |
| 4 |
DBIA
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
-$39.3K |
| 5 |
Morgan Stanley
New York
|
-$17K |
AVTX Hedge Fund Activity: Q3 2018 in Review
20 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2018, worth a combined $84.7M — up 15% from $73.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AVTX positions and 4 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, adding an estimated $4.95M. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $114K sold.
- 20 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2018, up from 18 in Q2 2018.
- Funds reported $84.7M of Avalo Therapeutics stock for Q3 2018, up 15% quarter-over-quarter.
- 6 funds opened new Avalo Therapeutics positions in Q3 2018 and 4 closed out, a net change of +2 holders.
- The largest Avalo Therapeutics buyer in Q3 2018 was Armistice Capital, an estimated $4.95M added.
- The largest Avalo Therapeutics seller in Q3 2018 was Boothbay Fund Management, an estimated $114K sold.
Based on aggregated 13F filings for Q3 2018.